Pre-Conference Workshop Day
Tuesday, 14th December 2021 | GMT
Workshop A: The Best Mouse Models for Cancer Research: Which One to Use
09.00 - 11.30
Preclinical tumour models are getting closer to in-human conditions, but are still a long way off – leading to large disparities between the modelled results and what we see in patients. Here we will explore the best mouse models for cancer research to progress your oncology candidate. Understand the tools you can use to provide robust data, boost translational confidence and improve the predictability of our current models.
In this workshop, we will explore the best-in-class methods to improving our predictions and getting the most from our preclinical models. Including a close look at:
• Genetically engineered mouse models (GEMM)
• PDX
• Orthotopic models
Workshop Leader
Chiara Ambrogio
Assistant Professor of Molecular Biology
University of Turin
Workshop B: Understanding and Choosing the Appropriate Humanized Mouse Platform for Your Drug Development Needs
12:00 - 15.00
- What is a humanized mouse? Approaches to humanization to understand main characteristics, advantages, and limitations of current platforms:
-
- Genetic humanization and creation of host strains
- Human PBMC humanization
- Human CD34 HSC humanization
- Applications of human immune cell engrafted mice
- Xenogeneic GvHD, a versatile platform for drug discovery in immune activation and suppression
- Immuno-oncology
- Checkpoint inhibitors
- Cell depletion
- Multi-specific antibodies
- CAR-T, NK, M
-
- Safety and Toxicity; In Vivo Assay for Cytokine Release Syndrome
- Round table discussion: Find out from experts and colleagues the details you need to apply these valuable tools for your research and drug discovery
Workshop Leader
Brian Soper
Senior Manager, Technical Information Sciences
The Jackson Laboratory
Workshop C: Patient-Derived Tumour Models for Personalised Therapeutics in Urological Cancers
15.30 - 18.00
With the complex human physiology and individual genome make-up, personalised and precision oncology are becoming more and more important. Personalised tumor models, such as tissue explants, organoids and PDX, will continue to play a crucial role to help us understand treatment response and select best treatment options.
This workshop will discuss the latest in personalised models for preclinical oncology studies and how they can be leveraged in your pipeline. We will address the contribution and translational value of preclinical patient-derived models including:
• 3D culture models
• Organotypic tissue slices
• Patient-derived xenograft models
Workshop Leader
Geertje van der Horst
Senior Scientist Leiden University
Medical Center
